Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026

Rhea-AI Summary

Protalix BioTherapeutics (NYSE American: PLX) will release its fiscal year 2025 financial results and provide a business update on March 18, 2026. Management will host a conference call and live webcast at 8:00 a.m. EDT to discuss results and recent corporate and regulatory developments.

Call-in numbers, webcast links, conference ID, and replay availability for two weeks on the company's investor events page are provided for investors and analysts.

News Market Reaction – PLX

-0.34%

-0.34% Session close to close

In the Mar 11 session, PLX declined 0.34%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the date and access details for Protalix’s FY 2025 financial results and busi...

Analysis

This announcement sets the date and access details for Protalix’s FY 2025 financial results and business update on March 18, 2026 at 8:00 a.m. EDT. It follows Q3 2025 results, where YTD revenue reached $43.6M (up 24% year-over-year), and recent EU approval of a new Elfabrio regimen that triggered a $25M milestone. Investors may focus on revenue trends, cash resources, and pipeline progress, particularly PRX‑115 and renal programs, when the full-year metrics are released.

Key Figures

Earnings release date: March 18, 2026 Conference call time: 8:00 a.m. EDT Conference ID: 13758983

3 metrics

Earnings release date March 18, 2026 Scheduled FY 2025 financial results and business update

Conference call time 8:00 a.m. EDT Management call to discuss FY 2025 results

Conference ID 13758983 Dial-in and webcast access code for FY 2025 call

Previous Earnings date Reports

1 past event · Latest: Nov 06 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 06	Earnings date notice	Neutral	-6.7%	Announced Q3 2025 results date and investor call details ahead of earnings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The last similar 'earnings date' notice on Nov 6, 2025 was followed by a -6.72% move, indicating prior pre-earnings scheduling headlines coincided with downside pressure.

Recent Company History

Over the past six months, Protalix combined operational progress with regular investor communications. A stockholder letter on Jan 5, 2026 outlined 2026 priorities and Phase 1 PRX‑115 data, while a December 2025 Secarna collaboration expanded its renal pipeline. Q3 2025 earnings on Nov 13, 2025 showed $43.6M YTD revenue, up 24% year-over-year, but the stock fell 9.81%. The prior earnings-date notice for that quarter on Nov 6, 2025 also saw a negative reaction of 6.72%, framing today’s FY 2025 earnings-date news in a context of cautious trading around such events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host conference call and webcast at 8:00 a.m. EDT

CARMIEL, Israel, March 11, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the fiscal year ended December 31, 2025 and provide a business update on March 18, 2026.

Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.

Conference Call Details:
Date: Wednesday, March 18, 2026
Time: 8:00 a.m. Eastern Daylight Time (EDT)
Toll Free: 1-877-423-9813
International: 1-201-689-8573
Israeli Toll Free: 1-809-406-247
Conference ID: 13758983
Call me™: http://bit.ly/4aOQNnE

The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.

Webcast Details:

The conference will be webcast live from the Protalix website and will be available via the following links:

Company Link: https://ir.protalix.com/news-events/events
Webcast Link: https://tinyurl.com/4jxzchdh
Conference ID: 13758983

Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio^®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.

Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-fiscal-year-2025-financial-results-and-business-update-on-march-18-2026-302710843.html

SOURCE Protalix BioTherapeutics, Inc.

FAQ

When will Protalix (PLX) announce fiscal year 2025 results and hold the conference call?

Protalix will announce fiscal year 2025 results and hold a conference call on March 18, 2026 at 8:00 a.m. EDT. According to the company, management will discuss the annual financial results and provide an update on recent corporate and regulatory developments during the call.

How can investors join the Protalix (PLX) March 18, 2026 webcast and conference call?

Investors can join via phone or live webcast using provided links and dial‑in numbers with Conference ID 13758983. According to the company, the webcast is on the investor events page and phone numbers include toll‑free and international options.

Will Protalix (PLX) provide a replay of the March 18, 2026 event and where can it be accessed?

A replay of the conference call will be available for two weeks on the company's investor events calendar. According to the company, the replay can be accessed via the Events section on the Protalix investor website at the same webcast link.

What preparation is recommended for participants joining the Protalix (PLX) March 18, 2026 call?

Participants are asked to access the call at least 15 minutes early to register and install any required audio software. According to the company, early access ensures timely registration and avoids technical delays for the conference call and webcast.

What topics will Protalix (PLX) cover during the March 18, 2026 earnings call?

Management will discuss the fiscal year 2025 financial results and provide an update on recent corporate and regulatory developments. According to the company, the call is intended to inform investors and analysts about financial performance and business progress.